[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337232-105":59,"doc-detail-337232-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","long-term-risks-and-benefits-of-oral-anticoagulation-in-atrial-fibrillation-patients-with-cancer-a-report-from-the-gloria-af-registry","Long-term risks and benefits of oral anticoagulation in atrial fibrillation patients with cancer - A report from the GLORIA-AF registry","","Anticoagulation in atrial fibrillation (AF) patients with concomitant cancer is difficult because cancer increases both embolic and bleeding risk. The benefits and harms of vitamin K antagonists versus non-vitamin K antagonist oral anticoagulants (NOACs) in this setting remain insufficiently clarified. Using the prospective global GLORIA-AF registry, outcomes were assessed across 3 years after characterizing prior cancer history. Cox models with propensity score matching compared event rates for mortality, stroke, embolism, and major bleeding.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/long-term-risks-and-benefits-of-oral-anticoagulation-in-atrial-fibrillation-patients-with-cancer-a-report-from-the-gloria-af-registry/337232/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/long-term-risks-and-benefits-of-oral-anticoagulation-in-atrial-fibrillation-patients-with-cancer-a-report-from-the-gloria-af-registry/337232.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is oral anticoagulation challenging in AF patients with cancer?","Question",{"text":112,"@type":113},"Because concomitant cancer substantially increases the risk of both embolism and bleeding in atrial fibrillation patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the main study outcome in the GLORIA-AF analysis?",{"text":117,"@type":113},"The primary outcome was a composite of all-cause mortality, stroke, transient ischemic attack, and systemic embolism.",{"name":119,"@type":110,"acceptedAnswer":120},"How did NOACs compare with VKA in cancer patients after propensity score matching?",{"text":121,"@type":113},"In cancer patients, NOAC use was associated with a lower risk of the primary composite outcome and thromboembolism compared with VKA, while major bleeding did not differ significantly.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337232,1790144172,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","DOI: 10. 1111/eci.14347  \nORIGINAL ARTICLE  \nLong-term risks and benefits of oral anticoagulation inatrial fibrillation patients with cancer: A report from the GLORIA-AF registry  \nMeng Li1,2  | Bi Huang1,3 | Steven Ho Man Lam1  | Hironori Ishiguchi1,4 | Yang Liu1,5 | Brian Olshansky6  | MennoV. Huisman7 | Tze-Fan Chao8,9  |  \nGregory Y. H. Lip1,10  \n1Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, and Liverpool Heart and Chest Hospital, Liverpool, UK  \n2Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China  \n3Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China 4Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan 5The Second Affiliated Hospital of Nanchang University, Nanchang, China 6Division of Cardiology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA  \n7Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands 8Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan  \n9Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan 10Department of Clinical Medicine, Aalborg University, Aalborg, Denmark  \nAbstract  \nBackground: Anticoagulation therapy in patients with atrial fibrillation (AF) and concomitant cancer can be challenging due to the significantly increased risk of both embolism and bleeding. Moreover, the benefits and risks of vitamin K antagonists (VKA, eg. warfarin) versus non-vitamin K antagonist oral anticoagulants (NOACs) in such patients are less well understood.  \nMethods: From the prospective, global, multi-centered Global Registry on LongTerm Antithrombotic Treatment inPatients with Atrial Fibrillation (GLORIA-AF), we characterized these patients according to their history of prior cancer when enrolled. All patients received anticoagulant therapy. The primary outcome was the composite of all-cause mortality, stroke, transient ischemic attack, systemic embolism. The secondary endpoints were all-cause mortality, cardiovascular death, stroke, major bleeding and thromboembolism during the 3 years follow-up period. Cox regression analyses were used to calculate the hazard ratio (HR) and confidence interval (CI) following propensity score matching (PSM) .  \nResults: Overall, among 16,700 patients enrolled in Phase III in GLORIA-AF, 1725 (10%) patients had concomitant cancer(s) at enrolment. After PSM, the primary outcome occurred in 250 (14.8%) of patients with cancer(s) and 160 (9.3%) without cancer(s) (HR, 1.62 [95% CI, 1.33–1.97], p \u003C .001) during the 3 years follow-up period. The risk of all-cause mortality was significantly higher in patients with cancer(s) versus non-cancer(s) (HR, 1.71 [95% CI, 1.37–2.12], p \u003C .001) . Inpatients with cancer(s), after PSM, the use of NOACs was associated with reduced risk of the primary outcome compared with that of VKA (HR, .69 [95% CI,.49–.99], p = .043), as well as a lower risk of thromboembolism (HR, .49 [95% CI,.24–1.00], p = .051), but the risk of major bleeding was not significantly different (HR, .87 [95% CI, .48–1.56], p = .635) . Subgroup analysis in patients with cancers  \n\n| Meng Li and Bi Huang contributed equally to this work. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation. |\n\nEur J Clin Invest. 2025;55:e14347 .  \n[https://doi.org/10.1111/eci.14347](https://doi.org/10.1111/ec","cbCaidFIJwJlX888","https://ap.wps.com/l/cbCaidFIJwJlX888","pdf",770660,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Keywords","[{\"question\":\"Why is oral anticoagulation challenging in AF patients with cancer?\",\"answer\":\"Because concomitant cancer substantially increases the risk of both embolism and bleeding in atrial fibrillation patients.\"},{\"question\":\"What was the main study outcome in the GLORIA-AF analysis?\",\"answer\":\"The primary outcome was a composite of all-cause mortality, stroke, transient ischemic attack, and systemic embolism.\"},{\"question\":\"How did NOACs compare with VKA in cancer patients after propensity score matching?\",\"answer\":\"In cancer patients, NOAC use was associated with a lower risk of the primary composite outcome and thromboembolism compared with VKA, while major bleeding did not differ significantly.\"}]","Long-term risks and benefits of oral anticoagulation in atrial fibrillation patients with cancer - A report from the GLORIA-AF registry | PDF",1790018235,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02955fae3d89bf64ad26a0a3172f3dd4.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e67ec23209c117ffa696f35c4eb2a56.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac119964bfda2e5c15973b2827a15214.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d92af6705dd0997dba25efee92328164.webp",980,1287]